Catalyst Wire Dossier Catalyst Wire Dossier

UX003

recombinant human beta-glucuronidase · Ultragenyx Pharmaceutical Inc
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for UX003, covering 2018-02-19 to 2019-10-16. Get the full timeline:

Most recent: Clinical Trial Update: Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age [Phase 2]

See pricing